Publications by authors named "S L Weinrich"
Background: Cyclin-dependent kinase 4/6 inhibitor (CDK4/6) therapy plus endocrine therapy (ET) is an effective treatment for patients with hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer (HR+/HER2- MBC); however, resistance is common and poorly understood. A comprehensive genomic and transcriptomic analysis of pretreatment and post-treatment tumors from patients receiving palbociclib plus ET was performed to delineate molecular mechanisms of drug resistance.
Methods: Tissue was collected from 89 patients with HR+/HER2- MBC, including those with recurrent and/or metastatic disease, receiving palbociclib plus an aromatase inhibitor or fulvestrant at Samsung Medical Center and Seoul National University Hospital from 2017 to 2020.
Machine learning algorithms provide detailed description of the anaerobic digestion process, but the impact of data preparation procedures and hyperparameter optimization has rarely been investigated. A genetic algorithm was developed for optimizing data preparation and model hyperparameters to simulate dynamic methane production from steady-state anaerobic digestion of agricultural residues at full-scale. A long short-term memory neural network was used as prediction model.
View Article and Find Full Text PDFFlexible biogas production can enable demand-oriented energy supply without the need for expensive gas storage expansions, but poses challenges to the stability of the anaerobic digestion (AD) process. In this work, biogas production of laboratory-scale AD of maize silage and sugar beets was optimized to cover the residual load of an electricity self-sufficient community using a simple process model based on first-order kinetics. Experiments show a good agreement between biogas demand, predicted, and measured biogas production.
View Article and Find Full Text PDFArticle Synopsis
- Lorlatinib is the leading treatment for ALK-positive non-small cell lung cancer, but patients can develop various mutations that make the drug less effective.
- After studying these mutations, researchers found that the most common ones were ALK G1202R and I1171N/S/T, which contribute to resistance against lorlatinib.
- The team also discovered new lorlatinib analogs that are more effective against specific mutations, suggesting a need for personalized treatment plans based on the type of mutation found in patients.